Reset filter
Keywords
Crohn Disease ×
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

12 Search results.

Relevance Rating New first Old first

Eligibility NCT01291810 Crohn's Disease - Eligibility

- 9/27/21 - 1 form, 2 itemgroups, 7 items, 2 languages
Itemgroups: Inclusion Criteria,Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01291810

Eligibility NCT00820365 Inflammatory Bowel Disease (IBD) - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 45 items, 2 languages
Itemgroups: Inclusion Criteria,Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00820365

Eligibility NCT00740103 Crohn's Disease - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 19 items, 2 languages
Itemgroups: Inclusion Criteria,Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00740103

Eligibility NCT00306215 Crohn's Disease - Eligibility

- 9/20/21 - 1 form, 3 itemgroups, 38 items, 2 languages
Itemgroups: Inclusion Criteria,Exclusion Criteria,Medical Concepts
ODM derived from http://clinicaltrials.gov/show/NCT00306215

Eligibility NCT01369342 Crohn's Disease - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 11 items, 2 languages
Itemgroups: Inclusion Criteria,Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01369342

Eligibility NCT01190839 Crohn's Disease - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 16 items, 2 languages
Itemgroups: Inclusion Criteria,Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01190839

Eligibility NCT00048295 Crohns Disease - Eligibility NCT00048295

- 9/17/21 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion,Exclusion
see http://clinicaltrials.gov/ct2/show/study/NCT00048295 ISIS 2302 is an antisense oligonucleotide drug that reduces the production of a specific protein called intercellular adhesion molecule (ICAM-1), a substance that plays a significant role in the increase of inflammation. People with Crohn’s disease have been shown to over-produce ICAM-1 in their gut tissues. Alicaforsen works by blocking ICAM-1 messenger RNA, the “instruction” molecule that is required for the production of ICAM-1 protein. This trial will examine effects of alicaforsen delivered by 2-hour intravenous infusion over a four-week period, compared to a placebo. Patients may remain on stable background 5-ASA, antibiotic, or immunosuppressive drugs, and prednisone (or equivalent) at </= 30 mg per day.

Eligibility NCT01363427 Crohn's Disease - Eligibility

- 4/20/14 - 1 form, 1 itemgroup, 4 items, 2 languages
Itemgroup: Inclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01363427

Eligibility NCT00739986 Crohn's Disease - Eligibility

- 4/16/14 - 1 form, 2 itemgroups, 10 items, 2 languages
Itemgroups: Inclusion Criteria,Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00408746

Eligibility NCT00160706 Crohn's Disease - Eligibility

- 4/13/14 - 1 form, 2 itemgroups, 6 items, 1 language
Itemgroups: Inclusion Criteria,Medical Concepts
ODM derived from http://clinicaltrials.gov/show/NCT00160706

Eligibility NCT00160524 Crohns Disease - Eligibility

- 4/13/14 - 1 form, 1 itemgroup, 2 items, 1 language
Itemgroup: Inclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00160524

Eligibility NCT00048295 Crohns Disease - Eligibility NCT00048295

- 4/11/14 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion,Exclusion
see http://clinicaltrials.gov/ct2/show/study/NCT00048295 ISIS 2302 is an antisense oligonucleotide drug that reduces the production of a specific protein called intercellular adhesion molecule (ICAM-1), a substance that plays a significant role in the increase of inflammation. People with Crohn’s disease have been shown to over-produce ICAM-1 in their gut tissues. Alicaforsen works by blocking ICAM-1 messenger RNA, the “instruction” molecule that is required for the production of ICAM-1 protein. This trial will examine effects of alicaforsen delivered by 2-hour intravenous infusion over a four-week period, compared to a placebo. Patients may remain on stable background 5-ASA, antibiotic, or immunosuppressive drugs, and prednisone (or equivalent) at </= 30 mg per day.

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial